NCT00412958

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

A Multicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 125 (actual)
• Sponsor: ThromboGenics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.

Conditions

• Vitrectomy

Interventions

Type	Name	Description
DRUG	Ocriplasmin 25µg	Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
DRUG	Ocriplasmin 75µg	Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
DRUG	Ocriplasmin 125µg	Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
DRUG	Placebo	Intravitreal injection of placebo

Timeline

• Start date: 2006-12-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2006-12-19
• Last updated: 2014-12-17
• Results posted: 2013-01-30

Locations

20 sites across 1 country: United States